USA - NASDAQ:OSUR - US68554V1089 - Common Stock
The current stock price of OSUR is 2.74 USD. In the past month the price decreased by -13.84%. In the past year, price decreased by -34.29%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ALC | ALCON INC | 24.47 | 36.92B | ||
| COO | COOPER COS INC/THE | 17.39 | 13.90B | ||
| SOLV | SOLVENTUM CORP | 11.36 | 11.97B | ||
| ALGN | ALIGN TECHNOLOGY INC | 14.26 | 9.99B | ||
| BLCO | BAUSCH + LOMB CORP | 34.74 | 5.29B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 23.53 | 5.18B | ||
| LNTH | LANTHEUS HOLDINGS INC | 9.03 | 3.92B | ||
| ICUI | ICU MEDICAL INC | 15.97 | 2.97B | ||
| XRAY | DENTSPLY SIRONA INC | 7.37 | 2.52B | ||
| HAE | HAEMONETICS CORP/MASS | 10.75 | 2.41B | ||
| UFPT | UFP TECHNOLOGIES INC | 22.32 | 1.49B | ||
| ESTA | ESTABLISHMENT LABS HOLDINGS | N/A | 1.39B |
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. The company is headquartered in Bethlehem, Pennsylvania and currently employs 501 full-time employees. The firm's product portfolio is divided into diagnostics products and sample management solutions. Its business consists of the development, manufacture, marketing and sale of diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its diagnostic products include tests for diseases including COVID-19, HIV, Hepatitis C and Syphilis that are performed on a rapid basis at the point of care. Its business also includes sample management solutions and services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.
ORASURE TECHNOLOGIES INC
220 E First St
Bethlehem PENNSYLVANIA 18015 US
CEO: Stephen S. Tang
Employees: 501
Phone: 15036416115
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. The company is headquartered in Bethlehem, Pennsylvania and currently employs 501 full-time employees. The firm's product portfolio is divided into diagnostics products and sample management solutions. Its business consists of the development, manufacture, marketing and sale of diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its diagnostic products include tests for diseases including COVID-19, HIV, Hepatitis C and Syphilis that are performed on a rapid basis at the point of care. Its business also includes sample management solutions and services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.
The current stock price of OSUR is 2.74 USD. The price increased by 1.48% in the last trading session.
OSUR does not pay a dividend.
OSUR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
ORASURE TECHNOLOGIES INC (OSUR) will report earnings on 2025-11-05, after the market close.
You can find the ownership structure of ORASURE TECHNOLOGIES INC (OSUR) on the Ownership tab.
The outstanding short interest for ORASURE TECHNOLOGIES INC (OSUR) is 5.52% of its float.
ChartMill assigns a fundamental rating of 2 / 10 to OSUR. OSUR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months OSUR reported a non-GAAP Earnings per Share(EPS) of -0.67. The EPS decreased by -286.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.47% | ||
| ROE | -13.4% | ||
| Debt/Equity | 0 |
8 analysts have analysed OSUR and the average price target is 6.12 USD. This implies a price increase of 123.36% is expected in the next year compared to the current price of 2.74.
For the next year, analysts expect an EPS growth of -241.31% and a revenue growth -34.82% for OSUR